Literature DB >> 16488332

Innate and adaptive immunity and the pathophysiology of psoriasis.

Anthony A Gaspari1.   

Abstract

Psoriasis is considered to be a genetically programmed disease of dysregulated inflammation, which is driven and maintained by multiple components of the immune system. The pathologic collaboration between innate immunity (mediated by antigen-presenting cells and natural killer T lymphocytes) and acquired immunity (mediated by T lymphocytes) results in the production of cytokines, chemokines, and growth factors that contribute to the inflammatory infiltrate seen in psoriatic plaques. This overview of the pathophysiology of psoriasis describes these events, and recent developments that have contributed to our understanding of the role of immune function in psoriasis. These developments include the creation of useful animal models and identification of new receptors and lymphocyte subtypes that may participate in the development of this chronic disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488332     DOI: 10.1016/j.jaad.2005.10.057

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  47 in total

1.  Are cutaneous microdialysis cytokine findings supported by end point biopsy immunohistochemistry findings?

Authors:  Florence Sjögren; Chris D Anderson
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

2.  HLA Antigens in Omani Psoriasis Vulgaris Patients.

Authors:  Fatma Al-Mamari; Ali Al-Shirawi; Dd Banodkar; Suliman Al-Hashmi; Faiza Al-Yahyaae; Mathew Varghese; Ja Raeburn
Journal:  Oman Med J       Date:  2009-01

3.  Identification of cell types, tissues and pathways affected by risk loci in psoriasis.

Authors:  Yan Lin; Pan Zhao; Changbing Shen; Songke Shen; Xiaodong Zheng; Xianbo Zuo; Sen Yang; Xuejun Zhang; Xianyong Yin
Journal:  Mol Genet Genomics       Date:  2015-11-12       Impact factor: 3.291

4.  Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome.

Authors:  Ananya Datta-Mitra; Smriti Kundu-Raychaudhuri; Anupam Mitra; Siba P Raychaudhuri
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

5.  A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.

Authors:  C Ritchlin; F Tausk
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

6.  Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining.

Authors:  Wing Man Lau; Alex W White; Charles M Heard
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

7.  Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response.

Authors:  Ayaluru Murali; Xiaojun Li; C T Ranjith-Kumar; Kanchan Bhardwaj; Andreas Holzenburg; Pingwei Li; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

Review 8.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

9.  Activation of keratinocyte protein kinase C zeta in psoriasis plaques.

Authors:  Yuming Zhao; Rita Fishelevich; John P Petrali; Lida Zheng; Malinina Alla Anatolievna; April Deng; Richard L Eckert; Anthony A Gaspari
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

10.  Biological markers in the etiology of psoriasis: Targeted treatment options.

Authors:  Catia de Felice; Georgiana Clare Marulli; Marco Ardigò; Enzo Berardesca
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.